When was Ixcells Biotechnologies founded?

Ixcells Biotechnologies was founded in 2014 and raised its 1st funding round 8 years after it was founded.

Where is Ixcells Biotechnologies located?

Ixcells Biotechnologies is headquartered in San Diego, United States.

Who is the current CEO of Ixcells Biotechnologies?

Dongmei Wu of Ixcells Biotechnologies.

How many employees does Ixcells Biotechnologies have?

As of Jul 01, 2024, the latest employee count at Ixcells Biotechnologies is 20.

Is Ixcells Biotechnologies a funded company?

Ixcells Biotechnologies is a funded company, having raised a total of $***** in its 1st and only funding round, a PE round on Sep 29, 2022.

When was the latest funding round of Ixcells Biotechnologies?

Ixcells Biotechnologies' latest funding was a $***** PE round on Sep 29, 2022, with participation from 1 investor.

Where does Ixcells Biotechnologies rank among its competitors?

Ixcells Biotechnologies ranks 462nd amongst 1948 active competitors, of which 456 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Ixcells Biotechnologies?

Ixcells Biotechnologies' top competitors include Synthego, Sutro Biopharma and Avidity Biosciences. Among them, Antheia secured the most recent funding round in January, 2026.

Ixcells Biotechnologies - 2026 Company Profile, Team, Funding & Competitors

Company Details

Ixcells biotech maintains patient-derived iPS for a wide range of diseases including neuronal diseases, cardiovascular diseases, hematological diseases, and diabetes. It also offers other primary cell lines, cell culture reagents, iPS derived cell lines, and RNA/Protein extract. Services offered by the company are customized cell based assays and screening services.

Website: ixcellsbiotech.com
Social
Email ID: *****@ixcellsbiotech.com, *****@ixcellsbiotech.com
Phone Number: +1 **********

Key Metrics

Founded Year

2014

Location

San Diego, United States

Stage

Late Stage

Latest Funding Round

PE, Sep 29, 2022, $*****

Investors

Great Point Partners

Ranked

462^nd among 1948 active competitors

Employee Count

20 as on Jul 01, 2024

Similar Companies

Synthego & 2659 more

View Ixcells Biotechnologies' full profile

Ixcells Biotechnologies has raised funding over 1 round. Its latest funding round was a PE round on Sep 29, 2022 for $*****. 1 investor participated in its latest round. Ixcells Biotechnologies has 1 institutional investor.

Here is the list of recent funding rounds of Ixcells Biotechnologies:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 29, 2022	5037034	PE	1040827	9160044	4463591	9439129

Access funding benchmarks and valuations. Sign up today!

View details of Ixcells Biotechnologies's funding rounds and investors

Ixcells Biotechnologies' employee count trend

Ixcells Biotechnologies has 20 employees as of Jul 24. Here is Ixcells Biotechnologies's employee count trend over the years:

Employee count trend for Ixcells Biotechnologies

Uncover Ixcells Biotechnologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ixcells Biotechnologies include Synthego, Sutro Biopharma and Avidity Biosciences. Here is the list of Top 10 competitors of Ixcells Biotechnologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
2nd	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	69/100
3rd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 19 others	68/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Citadel, New Enterprise Associates & 14 others	67/100
5th	Savara Pharma 2008, Austin (United States), Public	Developer of therapeutics for rare respiratory diseases	$67.8M	Austin Technology Incubator, Logos & 19 others	67/100
6th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
7th	Engine Biosciences 2014, Singapore (Singapore), Series A	Developer of platform technology for combinatorial genetics discovery	$86M	Polaris Partners, DHVC & 18 others	66/100
8th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, China Structural Reform Fund ... & 11 others	66/100
9th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
10th	Invenra 2011, Madison (United States), Series A	Pioneering bispecific and trispecific antibody discovery and development for novel therapies	$21.3M	Venture Investors, Venture Management & 4 others	65/100
462nd	Ixcells Biotechnologies 2014, San Diego (United States), Late Stage	Offers patented stem cells and cell lines	-	Great Point Partners	35/100